NNC 0151-0000-0000 + placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammation
Conditions
Inflammation, Rheumatoid Arthritis
Trial Timeline
Jan 1, 2011 → Feb 1, 2013
NCT ID
NCT01223911About NNC 0151-0000-0000 + placebo
NNC 0151-0000-0000 + placebo is a phase 2 stage product being developed by Novo Nordisk for Inflammation. The current trial status is completed. This product is registered under clinical trial identifier NCT01223911. Target conditions include Inflammation, Rheumatoid Arthritis.
What happened to similar drugs?
2 of 15 similar drugs in Inflammation were approved
Approved (2) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01223911 | Phase 2 | Completed |
| NCT01018238 | Phase 1 | Withdrawn |
Competing Products
20 competing products in Inflammation